IMNM · Immunome Inc.
$21.17
+0.27 (+1.29%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$2.43B
Shares
113.58M
Volume · Oct 5
1.22M
Avg daily vol (3M)
1.2M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.17
Open$20.79
Day$20.67–21.48
52W close$13.82–29.83
Avg vol 30d1.2M
Short int16.2M · 14.3% float · 20.6d
Short vol59%
DataOct 2020–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+82.2%
Trailing year
Short interest
14.3%
Latest settlement · 20.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−16%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−8%
trailing
YTD return
−1%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
1 of 203 funds reported for Sep 30 · net +23 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.30% of float · ▲ +3.9% MoM · 20.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
−23%
Y/Y
EPS growth
+51%
Y/Y
Free cash flow
$-200.6M
Balance sheet
$39.3M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $25 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
1 of 203 funds reported for Sep 30 · net +23 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.30% of float · ▲ +3.9% MoM · 20.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $21 · 46%
Range high $30
vs 200-day avg -7%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash, cash equivalents and marketable securities | $520M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMNM
this stock
Immunome Inc.
|
$2.43B | -1.4% | -23.2% | — | 14.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMNM | -2.4% | -20.9% | -7.6% | -1.6% | -1.4% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -3.6% | -21.5% | -19.1% | -3.2% | -15.1% |